- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Precision BioSciences Inc (DTIL)
Precision BioSciences Inc stock price live, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Precision BioSciences Inc real time stock price chart below.
What Is the Precision BioSciences Inc Stock Price Today?
The Precision BioSciences Inc stock price today is 5.3600.
What Is the Stock Symbol for Precision BioSciences Inc?
The stock symbol for Precision BioSciences Inc is "DTIL."
What Stock Exchange Does Precision BioSciences Inc Trade On?
Precision BioSciences Inc is listed and trades on the NASDAQ stock exchange.
Is Precision BioSciences Inc a Good Stock to Buy?
Determining whether Precision BioSciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DTIL quote. (ISIN: US74019P2074)
What Is the Precision BioSciences Inc Stock Price Today?
The Precision BioSciences Inc stock price today is 5.3600.
What Is the Stock Symbol for Precision BioSciences Inc?
The stock symbol for Precision BioSciences Inc is "DTIL."
What Stock Exchange Does Precision BioSciences Inc Trade On?
Precision BioSciences Inc is listed and trades on the NASDAQ stock exchange.
Is Precision BioSciences Inc a Good Stock to Buy?
Determining whether Precision BioSciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DTIL quote. (ISIN: US74019P2074)
NASDAQ
Currency in USD
5.3600
+0.3500(+6.99%)
Closed
After Hours
5.6000+0.2400(+4.4776%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.9800
5.4000
52 wk Range
3.6100
15.9700
DTIL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.98005.4000
52 wk Range
3.610015.9700
Precision BioSciences Inc is currently considered to be UndervaluedExplore our list of undervalued stocks for hidden opportunities
Precision BioSciences Inc is not on our AI-picked strategiesExplore current and previous stocks selected by AI
Try Warren AI research assistant for instant insights on Precision BioSciences IncFrom metrics, to news, charts, and even a SWOT analysis - you can ask anything!
What you should know about Precision BioSciences IncHolds more cash than debt on its balance sheetNet income is expected to grow this year
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DTIL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
33.6000
Upside
+526.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Precision BioSciences Inc Company Profile
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences Inc SWOT Analysis
ARCUS Advancement | Precision BioSciences' ARCUS gene editing platform approaches clinical milestone with PBGENE-HBV program, showcasing potential in treating genetic disorders |
Financial Runway | $140 million cash position extends operations into 2026, supporting pipeline development amid pre-revenue status and ongoing R&D investments |
Partnerships in Focus | Strategic collaborations with Novartis and Eli Lilly validate ARCUS platform, while recent changes reshape pipeline and control over key assets |
Market Outlook | Analysts maintain cautious stance with $34 price target, suggesting 205.8% upside potential contingent on successful clinical outcomes and commercialization |
Compare DTIL to Peers and Sector
Metrics to compare | DTIL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDTILPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.6x | −1.4x | −0.5x | |
PEG Ratio | 0.03 | 0.00 | 0.00 | |
Price/Book | 0.6x | 0.4x | 2.6x | |
Price / LTM Sales | 0.5x | 1.9x | 3.0x | |
Upside (Analyst Target) | - | 360.7% | 54.1% | |
Fair Value Upside | Unlock | 31.1% | 9.4% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.6000
(+526.87% Upside)
Earnings
Latest Release
May 13, 2024
EPS / Forecast
1.70 / -0.11
Revenue / Forecast
17.58M / 8.83M
People Also Watch
FAQ
What Is the Precision BioSciences (DTIL) Stock Price Today?
The Precision BioSciences stock price today is 5.36
What Stock Exchange Does Precision BioSciences Trade On?
Precision BioSciences is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Precision BioSciences?
The stock symbol for Precision BioSciences is "DTIL."
What Is the Precision BioSciences Market Cap?
As of today, Precision BioSciences market cap is 41.12M.
What is Precision BioSciences Earnings Per Share?
The Precision BioSciences EPS is 1.48.
From a Technical Analysis Perspective, Is DTIL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.